Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:274 (10 February), doi:10.1136/bmj.39115.419236.1F
| The first 100% of the full text of this article appears below. |
The settings of animal studies are very different from those of therapeutic studies in human patients.1 They need to be more similar.
In clinical studies a human subjects committee must approve the methods of the study, determining that it is of sufficient power to produce a meaningful result and that the risk:benefit ratio is acceptable. There should be animal subject committees similarly to scrutinise drug trials in animals. The task of such committees would be to assess sample size, randomisation of treatments, blinding of observers, selection of animal subjects, statistical methods, and elimination of biases that may be introduced by the pharmaceutical company that sponsors the work.
Alexander S D Spiers, retired professor of medicine
1 Cookham Dean, Berkshire spiersuk@btinternet.com